Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo

Antiviral Research

Volumn 89, Issue 1, 2011, Pages 26-34

  Chang, Jinhong ^a   Schul, Wouter ^b   Butters, Terry D ^c   Yip, Andy ^b   Liu, Boping ^b   Goh, Anne ^b   Lakshminarayana, Suresh B ^b   Alonzi, Dominic ^c   Reinkensmeier, Gabriele ^c   Pan, Xiaoben ^a   Qu, Xiaowang ^a   Weidner, Jessica M ^a   Wang, Lijuan ^a   Yu, Wenquan ^d   Borune, Nigel ^e   Kinch, Mark A ^f   Rayahin, Jamie E ^f   Moriarty, Robert ^f   Xu, Xiaodong ^d,g   Shi, Pei Yong ^b   Guo, Ju Tao ^a   Block, Timothy M ^a,d   more..

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d BARUCH S BLUMBERG INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g Enantigen Therapeutics Incorporated   (United States)

Author keywords

Glucosidase; Combination; Dengue virus; Imino sugar; Ribavirin

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; CM 10 18; CM 9 78; IMINOSUGAR; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; VIREMIA; VIRUS INHIBITION;

ADMINISTRATION, ORAL; ALPHA-GLUCOSIDASES; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; RIBAVIRIN; VIREMIA;

ANIMALIA; DENGUE VIRUS; MUS; RATTUS;

EID: 78650922795     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.11.002     Document Type: Article

References (35)

1. Alonzi D.S., Neville D.C., Lachmann R.H., Dwek R.A., Butters T.D. Glucosylated free oligosaccharides are biomarkers of endoplasmic-reticulum alpha-glucosidase inhibition. Biochem. J. 2008, 409(2):571-580.
2. Block T.M., Jordan R. Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs. Antivir. Chem. Chemother. 2001, 12(6):317-325.
3. Block T.M., Lu X., Mehta A.S., Blumberg B.S., Tennant B., Ebling M., Korba B., Lansky D.M., Jacob G.S., Dwek R.A. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat. Med. 1998, 4(5):610-614.
4. Block T.M., Lu X., Platt F.M., Foster G.R., Gerlich W.H., Blumberg B.S., Dwek R.A. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. U.S.A. 1994, 91(6):2235-2239.
5. Bridges C.G., Ahmed S.P., Kang M.S., Nash R.J., Porter E.A., Tyms A.S. The effect of oral treatment with 6-O-butanoyl castanospermine (MDL 28,574) in the murine zosteriform model of HSV-1 infection. Glycobiology 1995, 5(2):249-253.
6. Buckwold V.E., Wei J., Wenzel-Mathers M., Russell J. Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob. Agents Chemother. 2003, 47(7):2293-2298.
7. Butters T.D. Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders. Expert Opin. Pharmacother. 2007, 8(4):427-435.
8. Chang J., Wang L., Ma D., Qu X., Guo H., Xu X., Mason P.M., Bourne N., Moriarty R., Gu B., Guo J.T., Block T.M. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob. Agents Chemother. 2009, 53(4):1501-1508.
9. Datema R., Romero P.A., Rott R., Schwarz R.T. On the role of oligosaccharide trimming in the maturation of Sindbis and influenza virus. Arch. Virol. 1984, 81(1-2):25-39.
10. Dwek R.A., Butters T.D., Platt F.M., Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug Discov. 2002, 1(1):65-75.
11. 3. J. Acquir. Immune Defic Syndr. 1994, 7(2):139-147.
12. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347(13):975-982.
13. Gu B., Mason P., Wang L., Norton P., Bourne N., Moriarty R., Mehta A., Despande M., Shah R., Block T. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus. West Nile virus, dengue virus and hepatitis B virus. Antivir. Chem. Chemother. 2007, 18(1):49-59.
14. Helenius A., Aebi M. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 2004, 73:1019-1049.
15. Jordan R., Nikolaeva O.V., Wang L., Conyers B., Mehta A., Dwek R.A., Block T.M. Inhibition of host ER glucosidase activity prevents Golgi processing of virion-associated bovine viral diarrhea virus E2 glycoproteins and reduces infectivity of secreted virions. Virology 2002, 295(1):10-19.
16. Lindahl K., Stahle L., Bruchfeld A., Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005, 41(2):275-279.
17. Mackenzie J.S., Gubler D.J., Petersen L.R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis. West Nile and dengue viruses. Nat. Med. 2004, 10(12 Suppl.):S98-109.
18. Markland W., McQuaid T.J., Jain J., Kwong A.D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 2000, 44(4):859-866.
19. Mehta A., Ouzounov S., Jordan R., Simsek E., Lu X., Moriarty R.M., Jacob G., Dwek R.A., Block T.M. Imino sugars that are less toxic but more potent as antivirals, in vitro, compared with N-n-nonyl DNJ. Antivir. Chem. Chemother. 2002, 13(5):299-304.
20. Mellor H.R., Neville D.C., Harvey D.J., Platt F.M., Dwek R.A., Butters T.D. Cellular effects of deoxynojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides. Biochem. J. 2004, 381(Pt 3):867-875.
21. Noble C.G., Chen Y.L., Dong H., Gu F., Lim S.P., Schul W., Wang Q.Y., Shi P.Y. Strategies for development of dengue virus inhibitors. Antiviral Res. 2010.
22. Ouzounov S., Mehta A., Dwek R.A., Block T.M., Jordan R. The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy. Antiviral Res. 2002, 55(3):425-435.
23. Prichard M.N., Aseltine K.R., Shipman C. MacSynergy II. Version 1. 0. User's manual 1993, University of Michigan, Ann Arbor.
24. Qing M., Yang F., Zhang B., Zou G., Robida J.M., Yuan Z., Tang H., Shi P.Y. Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob. Agents Chemother. 2009, 53(8):3226-3235.
25. Rothwell C., Lebreton A., Young Ng C., Lim J.Y., Liu W., Vasudevan S., Labow M., Gu F., Gaither L.A. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 2009, 389(1-2):8-19.
26. Schul W., Liu W., Xu H.Y., Flamand M., Vasudevan S.G. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect Dis. 2007, 195(5):665-674.
27. Sessions O.M., Barrows N.J., Souza-Neto J.A., Robinson T.J., Hershey C.L., Rodgers M.A., Ramirez J.L., Dimopoulos G., Yang P.L., Pearson J.L., Garcia-Blanco M.A. Discovery of insect and human dengue virus host factors. Nature 2009, 458(7241):1047-1050.
28. Stevens A.J., Gahan M.E., Mahalingam S., Keller P.A. The medicinal chemistry of dengue fever. J. Med. Chem. 2009, 52(24):7911-7926.
29. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., Endy T.P., Raengsakulrach B., Rothman A.L., Ennis F.A., Nisalak A. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 2000, 181(1):2-9.
30. Wang Q.Y., Patel S.J., Vangrevelinghe E., Xu H.Y., Rao R., Jaber D., Schul W., Gu F., Heudi O., Ma N.L., Poh M.K., Phong W.Y., Keller T.H., Jacoby E., Vasudevan S.G. A small-molecule dengue virus entry inhibitor. Antimicrob. Agents Chemother. 2009, 53(5):1823-1831.
31. Whitby K., Pierson T.C., Geiss B., Lane K., Engle M., Zhou Y., Doms R.W., Diamond M.S. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 2005, 79(14):8698-8706.
32. Williams K.L., Zompi S., Beatty P.R., Harris E. A mouse model for studying dengue virus pathogenesis and immune response. Ann. N.Y. Acad. Sci. 2009, 1171(Suppl. 1):E12-23.
33. Wu S.F., Lee C.J., Liao C.L., Dwek R.A., Zitzmann N., Lin Y.L. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 2002, 76(8):3596-3604.
34. Yin Z., Chen Y.L., Schul W., Wang Q.Y., Gu F., Duraiswamy J., Kondreddi R.R., Niyomrattanakit P., Lakshminarayana S.B., Goh A., Xu H.Y., Liu W., Liu B., Lim J.Y., Ng C.Y., Qing M., Lim C.C., Yip A., Wang G., Chan W.L., Tan H.P., Lin K., Zhang B., Zou G., Bernard K.A., Garrett C., Beltz K., Dong M., Weaver M., He H., Pichota A., Dartois V., Keller T.H., Shi P.Y. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(48):20435-20439.
35. Zhang X.G., Mason P.W., Dubovi E.J., Xu X., Bourne N., Renshaw R.W., Block T.M., Birk A.V. Antiviral activity of geneticin against dengue virus. Antiviral Res. 2009, 83(1):21-27.